Menu
No results found.
Weekly Share Price & Valuation Overview
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, sells, and import/export of pharmaceuticals products worldwide. It's pipeline consist of OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4083/AMG 45, which is in Phase III and II clinical trial for the treatment of atopic dermatitis and prurigo nodularis, and asthma; OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A; ziftomenib, which is in Phase II and I clinical trial for the treatment of acute myeloid Leukemia and acute lymphoblastic leukemia; KHK4951, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; KK8123, which is in Phase I clinical trial for the treatment of x-linked hypophosphatemia; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK4277, which is in Phase I clinical trial for the treatment of systemic and cutaneous lupus erythematosus; and KK2260 and KK2269 that are in Phase I clinical trial for the treatment of solid tumors. It also develops POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein that produces platelet; Crysvita, a recombinant human monoclonal IgG1 antibody; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and LUMICEF, a biological treatment for moderate to severe plaque psoriasis. In addition, it offers G-Lasta; Duvroq; PHOZEVEL; KK8398; KHK4827; and OTL-200. It has an agreement with Amgen Inc. and Kura Oncology. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
- Healthy operating margin (≥15%) indicates efficient core operations.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Revenue growth ≥10% indicates solid top-line momentum.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Market Cap Total equity value of the company (share price × shares outstanding).
- JPY 1.38T
- Enterprise Value Operating value: market cap + total debt − cash.
- JPY 1.17T
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- JPY 493.24B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- JPY 358.23B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- JPY 109.33B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- JPY 940.76
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 73.46
- Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
- 2.28%
- Shares Outstanding
- 523.49M
- Float Shares
- 234.42M
- Implied Shares Outstanding
- 523.49M
- Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
19.00%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
22.17%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
72.63%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
7.79%
- Revenue Growth Strong Year-over-year revenue growth.
-
20.00%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
20.45%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 2.21
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.03
- Total Cash Cash and equivalents.
- JPY 234.60B
- Total Debt Short + long-term interest-bearing debt.
- JPY 23.00B
- Net Debt Net Cash Total debt − cash (negative = net cash).
- JPY -211.61B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 0.21
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- JPY 60.87B
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
12.34%
- Cash Conversion (OpCF/EBITDA)
- 0.56
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.